Everything you need to know about what it would take for the FDA to approve a COVID-19 vaccine

Johnson & Johnson stock underperforms Tuesday when compared to competitors

Merck’s Lung Cancer Drug Is a Blockbuster. Other Companies Are Starting to Challenge Its Dominance.

Vaccinex's stock falls after investigational drug fails Huntington's disease study

Johnson & Johnson stock falls Monday, underperforms market

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer

First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS >50%)

LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Johnson & Johnson stock underperforms Thursday when compared to competitors

Pfizer Vaccine Business Much More Than Covid-19

Johnson & Johnson stock falls Wednesday, still outperforms market